Paclitaxel (Taxol) is a widely used chemotherapeutic agent in the treatment of several tumors. However, its use is often associated with the generation of peripheral neuropathic pain expressed as mechanical allodynia and thermal hyperalgesia. The molecular mechanism behind this debilitating side effect is obscure, and efficient drugs for its prevention are required. We sought to clarify the cellular changes in the involved nociceptor types underlying paclitaxel-induced neuropathic pain and to test for an alleviating effect of gabapentin treatment in a murine model of paclitaxel-induced neuropathic pain. We found that a single treatment with paclitaxel (4 mg/kg i.p.) led to a decrease in both thermal and mechanical nociceptive thresholds as well as a reduction in the thresholds for 250-Hz (A␦-fiber) and 2000
Paclitaxel (Taxol) is widely used in cancer chemotherapy for the treatment of solid carcinomas (Kohler and Goldspiel, 1994; Socinski, 1999) . Its mechanism is known to involve an increase in the stability of tubulin polymers and to inhibit cellular replication (Schiff et al., 1979; Horwitz, 1992) . However, it has serious side effects such as peripheral neuropathic pain (Rowinsky et al., 1993; Chaudhry et al., 1994; Cavaletti et al., 1995; Forsyth et al., 1997) , which become more marked with continued therapy. In some cases, the side effects may outweigh the beneficial effects on life quality, necessitating a dose reduction [TAXOL (paclitaxel) package insert, Bristol-Myers Squibb Company, 2003 ]. However, the molecular mechanism underlying paclitaxel-induced neuropathic pain is enigmatic, and no therapeutics for its prevention are known.
Recently, the anticonvulsant gabapentin has proven effective in the treatment of neuropathic pain, and in neuropathic pain models such as the peripheral nerve ligation and diabetic neuropathic pain model, gabapentin inhibits thermal hyperalgesia and tactile allodynia (Hunter et al., 1997; Hwang and Yaksh, 1997; Cesena and Calcutt, 1999; Miki et al., 2001; Luo et al., 2002) . Although gabapentin was originally designed as a structural analog of the neurotransmitter GABA, it was revealed that gabapentin binds with highaffinity to Ca␣ 2 ␦-1 (Gee et al., 1996) , which most likely accounts for its analgesic effects (Cheng and Chiou, 2006) . Furthermore, gabapentin has been reported to inhibit highthreshold Ca 2ϩ channels and to modulate synaptic neurotransmission (Patel et al., 2000; Shimoyama et al., 2000; Sutton et al., 2002; Maneuf et al., 2004) . In addition, Luo et al. (2002) reported that gabapentin efficacy is correlated with the increase of Ca␣ 2 ␦-1 in DRGs in peripheral nerve injury models.
In the present study, we demonstrated that gabapentin inhibits paclitaxel-induced peripheral neuropathic pain in mice. Furthermore, Neurometer tests, which are known to determine nociceptor sensitivity as well as to distinguish between the different types of sensory neurons in humans and rodents (Masson and Boulton, 1991; Pitei et al., 1994; Kiso et al., 2001) , showed an A-fiber-specific hypersensitiza-(denaturation) and 1 min at 60°C (annealing extension). The Ca␣ 2 ␦-1 mRNA levels were evaluated by comparison with glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Primer sequences were as follows: Ca␣ 2 ␦-1, (forward) 5Ј-CTC ATG CAA GCG GAA CAG ACT TCT-3Ј and (reverse) 5Ј-TCA AAG CAG ACA TCA GGT CCT TT-3Ј corresponding to the mouse Ca␣ 2 ␦-1 gene (NCBI accession no. NM_009784) ; and GAPDH, (forward) 5Ј-TAT GAC TCC ACT CAC GGC AAA T-3Ј and (reverse) 5Ј-GGG TCT CGC TCC TGG AAG AT-3Ј corresponding to the mouse GAPDH (NCBI accession no. NM_001001303). In all cases, the validity of amplification was confirmed by the presence of a single peak in the melting temperature analysis and linear amplification against the PCR cycles.
Western Blot Analysis. On days 7, 14, and 28 after paclitaxel treatment, the L4-6 DRGs were removed for Western blot analysis. Mixed L4-6 DRG protein (30 g) were applied to an SDS-polyacrylamide gel (8%). The anti-Ca␣ 2 ␦-1 antibody (Sigma-Aldrich) diluted 1:200 (Inoue et al., 2004) was used, and anti-␤-tubulin antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) diluted 1:1000 was used as internal control. Horseradish peroxidase-labeled rabbit antibody was used as second antibody at 1:2000. Visualization of immunoreactive bands was performed by Light Capture (AE-6960/C/ FC; Atto, Tokyo, Japan) with an enhanced chemiluminescent substrate for the detection of horseradish peroxidase, SuperSignal West Pico Chemiluminescent Substrate (Pierce Chemical, Rockford, IL). The intensities of immunoreactive bands were analyzed by NIH Image Software (Bethesda, MD) for Macintosh.
Immunohistochemistry. The immunohistochemical analyses were performed as described previously (Inoue et al., 2004) . In brief, mice were deeply anesthetized with sodium pentobarbital (50 mg/kg i.p.) and perfused transcardially with 20 ml of potassium-free phosphate-buffered saline (K ϩ -free PBS; pH 7.4) followed by 50 ml of 4% paraformaldehyde solution. The L4-6 DRGs were removed, postfixed for 3 h, and cryoprotected overnight in 25% sucrose solution. The DRGs were fast-frozen in cryo-embedding compound on a mixture of ethanol and dry ice and stored at Ϫ80°C until use. DRGs were cut at 10-m thickness, thaw-mounted on a silane-coated glass slides, and air-dried overnight at room temperature. Before immunolabeling, antigen unmasking was performed by microwave treatment for 15 min in 10 mM citrate buffer, pH 6.0. DRG sections were incubated with excess blocking buffer containing 2% skim milk in 0.1% Triton X-100 in K ϩ -free PBS and subsequently reacted overnight at 4°C with anti-Ca␣ 2 ␦-1antibodies (1:200; Sigma-Aldrich) in 2% bovine serum albumin/0.1% Triton X-100 in K ϩ -free PBS. The sections were then placed in fluorescein isothiocyanate-conjugated anti-rabbit IgG (1:200; Santa Cruz Biotechnology, Inc.) for 2 h at room temperature. All sections were treated with Permafluor (Thermo Shandon, Pittsburgh, PA) and coverslipped and evaluated by microscopy (Keyence, Tokyo, Japan).
Measurements of DRG neuron diameters were done using the BZ Image Measurement software (Keyence). Total cell counts were carried out in bright field images as reported previously (Josephson et al., 2001; Dai et al., 2004) . Therefore, the quantification of the data may represent a biased estimate of the actual number of neurons. However, to determine the Ca␣ 2 ␦-1 positive neuron profile, we have carried out the counts using only neurons with clearly visible nuclei. In this experiment, we divided neurons into two groups, small-and medium/large-sized neurons. We used 24 m in diameter as dividing line between small-and medium/large-sized neurons (Gold et al., 1996; Hiruma et al., 2000) . In total, 1684 DRG neurons from vehicletreated mice (n ϭ 3) and 2724 DRG neurons from paclitaxel-treated mice (n ϭ 4) were measured.
Statistical Analysis. The behavioral time-course data were analyzed using a Student's t test to detect differences between vehicleand paclitaxel-treated groups. The behavioral data on gabapentin and the RT-PCR data as well as the Western blot data of Ca␣ 2 ␦-1 were analyzed using a one-way and Tukey multiple comparison post 
Results
Paclitaxel-Induced Thermal Hyperalgesia and Mechanical Allodynia. We treated mice with 4 mg/kg paclitaxel single (i.p. or i.v.) or multiple times (four i.p. injections on alternate days; days 0, 2, 4, and 6) and evaluated the threshold in several nociceptive tests from preinjection (control) to 4 weeks after the first treatment. No significant side effects such as ascites, loss of body weight, or alopecia was observed in this experimental schedule. A single i.p. injection of 4 mg/kg paclitaxel led to a decreased threshold in the paw pressure test, which was significant at 1 and 2 weeks after treatment but increased to baseline level at week 4 posttreatment (Fig. 1A) . When comparing the mechanical allodynia after a single i.p. injection, multiple i.p. injections, or single i.v. injection of paclitaxel, no significantly different outcomes were observed, between the numbers of administrations or the route, as shown as the AUC values for the paw pressure test from week 1 to 4 after treatment (Fig. 1B ). The thermal nociceptive threshold level decreased in a manner similar to the decrease in threshold for mechanical allodynia, although the effect was less pronounced. However, the effect was significant 2 weeks after a single i.p. injection of paclitaxel (Fig. 1C) . Based on these results, we determined to adopt the single i.p. injection for the paclitaxel-induced neuropathic pain model in mice and to evaluate the effect of gabapentin 2 weeks after treatment, which was the peak time point of neuropathic pain.
Blockade of Paclitaxel-Induced Neuropathic Pain by Gabapentin. Gabapentin, injected i.p. 30 min before behavioral tests, inhibited mechanical allodynia 2 weeks after paclitaxel treatment (4 mg/kg; single i.p. injection) in a dosedependent manner from 3 to 30 mg/kg, whereas 30 mg/kg gabapentin did not cause any significant effects in vehicletreated mice (Fig. 1D) . The duration of the analgesic effect from treatment with 30 mg/kg gabapentin lasted for more than 24 h, but the significant effect had vanished by 48 h after treatment (Fig. 1E) . Moreover, gabapentin injection (30 mg/kg i.p.) 2 weeks after paclitaxel treatment reversed thermal hyperalgesia within 30 min. However, gabapentin treatment of vehicle-treated mice did not affect the thresholds of thermal paw withdrawal latency (Fig. 1F) .
Paclitaxel-Induced Myelinated A-Fiber-Specific Hypersensitization. Transcutaneous nerve stimuli with each of the three sine wave pulses of different frequencies of 5, 250, and 2000 Hz to activate C-, A␦-, and A␤-fibers, respectively (Katims, 1997; Lengyel et al., 1998) , were applied to the right hind paw of the mice, and the intensity (microampere) was gradually increased. Thresholds were determined, at which paw withdrawal was observed, from preinjection (control) to 4 weeks after paclitaxel treatment (Fig. 2A) . The reduction in threshold by the 250-Hz (A␦) and 2000-Hz (A␤) stimuli at 1 and 2 weeks after paclitaxel treatment (4 mg/kg; single i.p. injection) had vanished 4 weeks after treatment. No significant change in the threshold by 5-Hz (C) stimuli was observed at any time. These results suggest that paclitaxel induces myelinated A␦-and A␤-fiber-specific hypersensitization.
Blockade of Paclitaxel-Induced Myelinated A-FiberSpecific Hypersensitization by Gabapentin. Gabapentin injection (30 mg/kg i.p.) 2 weeks after paclitaxel treatment reversed the hyperalgesia within 30 min as determined by 250-Hz (A␦) and 2000-Hz (A␤) stimulations. However, gabapentin treatment of vehicle-treated mice did not affect the thresholds of 250-Hz (A␦) and 2000-Hz (A␤) stimuliinduced responses (Fig. 2B) .
Increased Expression of Ca␣ 2 ␦-1 mRNA and Protein in DRG after Paclitaxel Treatment. We removed L4-6 DRGs at days 3, 7, and 14 after paclitaxel treatment, and Ca␣ 2 ␦-1 mRNA expression was quantified by RT-PCR analysis and compared with GAPDH mRNA expression. The specificity of the PCR primers was confirmed by the occurrence of a single peak in the melting curves for the PCR Fig. 1 . Paclitaxel-induced neuropathic pain and antinociceptive effect of gabapentin. A, time course of paclitaxel-induced mechanical allodynia from preinjection (control) to 4 weeks post-treatment. B, summation of paclitaxel-induced mechanical allodynia determined as the AUC from week 1 to 4 in response to a single i.p. injection, single i.v. injection, or four i.p. injections on alternate days (multi). C, time course of paclitaxel-induced thermal hyperalgesia from preinjection to 4 weeks after treatment. D, dose-dependent analgesic effects of gabapentin in mechanical paw pressure tests 2 weeks after paclitaxel treatment. E, time course of gabapentin (30 mg/kg)-induced analgesia 2 weeks after paclitaxel treatment (4 mg/kg i.p.). F, analgesic effects of gabapentin in thermal paw withdrawal tests 2 weeks after paclitaxel treatment (4 mg/kg i.p.). Animals were analyzed 30 min after 30 mg/kg gabapentin treatment. PWT, paw withdrawal threshold, PWL, paw withdrawal latency; C, control; Sal, saline; and GBP, gabapentin. ‫,ء‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.01 versus control (vehicle). #, p Ͻ 0.05; ##, p Ͻ 0.01 versus paclitaxel/saline. Data are presented as mean Ϯ S.E.M. from experiments using at least six mice.
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at ASPET Journals on August 30, 2017 jpet.aspetjournals.org products, and the efficiency of the reaction was found to be approximately 100% shown by a threshold cycle versus sample-dilution plot (Fig. 3A) . Ca␣ 2 ␦-1 mRNA expression was slightly but not significantly increased at day 3, but a larger and significant increase was observed at day 7 in paclitaxeltreated mice compared with controls (Fig. 3A) . At day 14, the Ca␣ 2 ␦-1 mRNA expression was reduced to control level.
Moreover, we removed L4-6 DRGs at days 7, 14, and 28 after paclitaxel treatment, and Ca␣ 2 ␦-1 protein expression was quantified by Western blot analysis. The result indicated that Ca␣ 2 ␦-1 up-regulation was significant at day 7, maximum at day 14, and returned to baseline level 28 days postpaclitaxel injection (Fig. 3B ).
Increased Expression of Ca␣ 2 ␦-1 in Medium/LargeSized DRG Neurons following Paclitaxel Treatment. We detected Ca␣ 2 ␦-1 protein expression in DRGs at day 14 after treatment using immunohistochemistry. In vehicletreated mice, Ca␣ 2 ␦-1 expression was mainly localized to small-diameter DRG neurons (Fig. 4A) , whereas in paclitaxel-treated mice, Ca␣ 2 ␦-1 protein expression was both observed in small-diameter DRG neurons and in medium/largediameter DRG neurons (Fig. 4A) . The total amount of neurons in the DRGs, which stained positive for Ca␣ 2 ␦-1 protein, was counted and their individual sizes measured both in paclitaxel-and vehicle-treated mice. A significant increase in the frequency of stained neurons was found in the from experiments using at least six mice. Fig. 3 . Expression of Ca␣ 2 ␦-1 mRNA and protein in L4-6 DRGs after paclitaxel treatment. A, top panel, dissociation curves of PCR products from reactions using primers specific for mRNA encoding Ca␣ 2 ␦-1 and GAPDH, and amplification efficiency analysis. Bottom panel, quantitative RT-PCR analysis. Ca␣ 2 ␦-1 and GAPDH mRNAs in L4-6 DRGs on days 3, 7, and 14 after paclitaxel treatment were measured and Ca␣ 2 ␦-1 was normalized to GAPDH. The graph shows the relative amount of Ca␣ 2 ␦-1 mRNA in paclitaxeltreated mice compared with the controls. B, Western blot analysis. Ca␣ 2 ␦-1 and ␤-tubulin protein in L4-6 DRGs 7, 14, and 28 days after paclitaxel treatment was measured, and Ca␣ 2 ␦-1 was normalized to ␤-tubulin. The graph shows the relative amount of Ca␣ 2 ␦-1 protein in paclitaxeltreated mice compared with the controls. Photograph shows representative data. ‫,ء‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.01 versus control (C). Data are presented as mean Ϯ S.E.M. from experiments using at least eight mice. paclitaxel-treated mice compared with vehicle-treated controls (Fig. 4B) . Furthermore the cell size measurements showed that the increased number of Ca␣ 2 ␦-1-stained neurons reflected an increased expression of Ca␣ 2 ␦-1 in medium/ large-sized neurons, whereas the number of positively stained small neurons remained almost the same between vehicle-and paclitaxel-treated groups (Fig. 4, C and D) . However, no significant difference in the general size distribution of DRG neurons was found between the two groups, supporting the notion that the increased Ca␣ 2 ␦-1 protein expression indeed resulted from an up-regulation in medium/large-sized neurons (Fig. 4C ).
Discussion
Here, we found that single administration of paclitaxel at a dose of 4 mg/kg i.p. caused peripheral neuropathic pain. According to the paclitaxel injection prescribing information sheet, the recommended dose is 135 to 175 mg/m 2 [TAXOL (paclitaxel) package insert, Bristol-Myers Squibb Company, 2003], which is converted into approximately 3.6 to 4.7 mg/kg (height, 1.7 m; weight, 65 kg; Du Bois formula). In addition, it states that paclitaxel should be given every 3 weeks in clinical states. However, in previous experimental studies, the paclitaxel administration has been performed multiple times on consecutive/alternate days or in a single but high dose (Authier et al., 2000; Dina et al., 2001; Polomano et al., 2001; Flatters and Bennett, 2004; Smith et al., 2004) . Therefore, the present finding seems to have some advantages. We conclude that the protocol using single administration of 4 mg/kg paclitaxel is a proper and easy approach to study paclitaxel-induced neuropathic pain.
In our experimental model, we observed mechanical allodynia, thermal hyperalgesia, and A-fiber specific hypersensitization using the Neurometer test. The Neurometer test is widely used clinically in the evaluation of sensory function in humans with complex regional pain syndrome or other types of peripheral neuropathic pain, which can result from common diseases such as diabetes mellitus (Masson and Boulton, 1991; Katims, 1997; Lengyel et al., 1998) . Our results are supported by previous data from animal models of paclitaxelinduced hypersensitivity (Smith et al., 2004) as well as Neurometer analysis of paclitaxel-treated patients, which also show A␤-fiber hypersensitivity, as determined by stimulating the median nerve with 2000-Hz pulses (Doi et al., 2003) . Therefore, we conclude that our model is useful for investigating the mechanism by which paclitaxel induces neuropathic pain and for testing new drug candidates.
Frequent reports of the alleviating effect of gabapentin treatment in various models of neuropathic pain such as the peripheral nerve ligation model and diabetic neuropathic pain models, have been published (Hunter et al., 1997; Hwang and Yaksh, 1997; Cesena and Calcutt, 1999; Miki et al., 2001; Luo et al., 2002) . The present study is the first to report an antinociceptive effect of gabapentin on paclitaxelinduced neuropathic pain in mice. We evaluated the effect by EPW tests as well as conventional nociceptive tests measuring mechanical nociception. Gabapentin revealed specific analgesic effects against paclitaxel-induced mechanical allodynia, thermal hyperalgesia, and A-fiber hypersensitization without affecting the pain threshold of naive mice. These results suggest that gabapentin could be used to treat paclitaxel-induced neuropathic pain in the clinic.
Referring to the mechanism of antinociceptive effects of gabapentin, we measured the expression of Ca␣ 2 ␦-1, which is known to possess gabapentin-binding properties (Gee et al., 1996) . We first demonstrated that the expression of Ca␣ 2 ␦-1 jpet.aspetjournals.org mRNA and protein was increased in the DRGs of paclitaxeltreated mice. The difference in the peak time point between mRNA and protein expression seems to be attributable to the longer life time of protein. It should be noted that the time course of Ca␣ 2 ␦-1 protein expression was very close to that of paclitaxel-induced neuropathic pain (Figs. 1, A and C, and 2A). Interestingly, immunohistochemistry revealed that Ca␣ 2 ␦-1 protein was increased in medium/large-diameter neurons following paclitaxel treatment. Because the function of the calcium channel containing Ca␣ 2 ␦-1 is related to modulation of synaptic neurotransmission (Patel et al., 2000; Shimoyama et al., 2000; Maneuf et al., 2004) , up-regulation of Ca␣ 2 ␦-1 expression in medium/large-sized neurons may contribute to the paclitaxel-induced mechanical allodynia and A-fiber-dependent hypersensitization. Recently, we have reported that Ca␣ 2 ␦-1 is up-regulated in medium/large-sized DRG neurons following peripheral nerve injury or intrathecal injection of lysophosphatidic acid, an initiator of neuropathic pain (Inoue et al., 2004) . Luo et al. (2002) reported that inhibitory effects of gabapentin on neuropathic pain correlate to Ca␣ 2 ␦-1 expression. Gabapentin sensitivity and Ca␣ 2 ␦-1 up-regulation were observed in spinal nerve ligation, spinal nerve transection, sciatic nerve chronic constriction injury, and diabetic models but not in the vincristine-induced neuropathic pain model. In the present study, we confirmed the gabapentin sensitivity and Ca␣ 2 ␦-1 up-regulation in the paclitaxel-induced neuropathic pain model. It is interesting that the gabapentin sensitivity and Ca␣ 2 ␦-1 up-regulation differed between the vincristine and paclitaxel models, when taken into account that both drugs are known to act through tubulin assembly. Although the underlying mechanism remains to be determined, it might be attributed different manners of action; disruption of tubulin assembly by vincristine and increasing stabilization by paclitaxel (Kohler and Goldspiel, 1994) .
In conclusion, we report that paclitaxel induces A-fiber hypersensitization and novel expression of Ca␣ 2 ␦-1 in medium/large-sized DRG neurons, which may functionally contribute to mechanical allodynia and hyperalgesia. Furthermore, we identify gabapentin as a potential therapeutic agent for paclitaxel-induced peripheral neuropathic pain.
